SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Cistron Biotechnology(CIST)$.30
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: John Metcalf who wrote (2497)10/4/1999 4:53:00 AM
From: Walter Morton  Read Replies (2) of 2742
 
Thanks John. However, the stock goes up and down all the time. Of the 20+ million shares outstanding there is very little trading going on. It seems to me that if the market were afraid about something the trading volume would be much higher than what it has been during the last few days and years.

I think the people who own most of the stock are at the Universities that gave the patents to CIST. They don't seem to be worried. So, why should the little guy who knows very little about the technology be worried?

I agree that CIST has been slow to create a major product out of IL-1b, but they did successfully create ICE (which took a few years). This past 10-K mentioned more actual testing of the technology than I have ever read before. It seems that outsourcing the R&D has sped up the R&D process.

Frankly, I don't believe CIST knew about PAI-2 being in Phase II clinical trials until that email was posted to the thread from Biotech Australia. Genome Securities would have included that information in the sales pitch. Anyway, the PAI-2 technology is the closes of all to potentially becoming a marketable product. If all else fails CIST could probably sue somebody into a merger agreement.

With just a few employees I believe that the Millions in cash (plus another $3 million next month) could sustain CIST for several years until it finish its research and clinical trials. Once clinical trials are completed it should be much easier to find marketing partners.

If CIST knows that it will never get that $31 million from PMC and that the PAI-2 clinical trials will be a failure, then CIST should liquidate the company NOW!!!
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News